A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

NCT05306223 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

212

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis, Multidrug-Resistant

Interventions

DRUG: Bedaquiline
DRUG: Levofloxacin
DRUG: Linezolid
DRUG: Cycloserine
DRUG: Clofazimine
DRUG: Pyrazinamide
DRUG: Protionamide

Sponsor

Beijing Chest Hospital